HCM News and Press, HUTCHMED (China) Limited From 05/16/22

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) announces that Mr Lefei Sun has been appointed as a Non-Executive Director with effect from May 16, 2022 and he...

Inmagene Receives FDA IND Clearance for a Third Generation BTK Inhibitor Targeting Immunological Diseases PR Newswire SAN DIEGO and SHANGHAI , May 15, 2022 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") announces that today the U.S. Food and...

China’s leading biotechnology and other health care companies have continued to grow revenues rapidly over the past two years and are expected to see strong growth in the years to come. Recently, concerns over domestic regulation, increased domestic competition, US Food and Dru...

OrbiMed Asia V plans to raise $1.1 billion, OrbiMed Flagship IX seeks $1.9 billion and OrbiMed Royalty & Credit Opportunities $1.75 billion. Shanghai Jemincare Pharmaceuticals out-licensed global rights (ex-China) for a novel pain medication to Orion Corporation, a Finnish pharmac...

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday, May 10 and Wednesday, May 11, featuring live webcast presentations from international companies with American Depos...

Gainers: Redbox Entertainment (RDBX) +48%. Blue Apron Holdings (APRN) +36%. Accolade (ACCD) +28%. Forge Global Holdings (FRGE) +22%. Hilltop Holdings (HTH) +19%. The Oncology Institute (TOI) +18%. OppFi (OPFI) +18%. Seer (SEER) +16%. Companhia Energetica de Minas Gerais (CIG) +16%. Silk Road ...

Gainers: Silk Road Medical (SILK) +12%. Clene (CLNN) +6%. BioCardia (BCDA) +2%. Veru (VERU) +2%. ERYTECH Pharma (ERYP) +1%. Losers: Global Cord Blood (CO) -28%. Zosano Pharma (ZSAN) -21%. Vaxxinity (VAXX) -17%. HUTCHMED (China) (HCM)...

The U.S. Food and Drug Administration (FDA) rejected Hutchmed's (China) (NASDAQ:HCM) application seeking approval of surufatinib to treat certain neuroendocrine tumors, noting that the data submitted did not support an approval and a multi-regional clinical trial is required. The FDA had...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 02, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) announced that the U.S. Food and Drug Administration (“FDA” or the “...

Chinese President Xi Jinping directed that the government is committed to "deliver its economic growth target and support the healthy growth of internet platform companies." The edict from Xi himself is highly significant. He is committed to leveraging Alibaba and its peers to help me...